4 results
To assess the impact of 10 intravenous infusions of 3 mg/kg CER-001 versus placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS, when administered to subjects presenting with an ACS event.
The current proposal wants to examine the efficacy and cost-efficiency of a telemonitoring solution to improve medication adherence in chronic heart failure patients, to enhance the clinical state of the patients and to reduce health care…
Evaluate the effects of CER-001 - adminstered as iv infusion - on plaque size/burden in arteries, plaque inflammation in the artery wall and the rate of cholesterol transport in the body
Objectives:• To allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy orcombination) protocols, who are tolerating study drug and displaying clinical benefit.• To assess long-term safety and…